|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30.01.26 - 08:00
|
AstraZeneca agrees obesity and T2D deal with CSPC (Cision)
|
|
|
30 January 2026
AstraZeneca enhances its weight management portfolio through collaboration agreement with CSPC Pharmaceuticals
Agreement includes eight programmes, including a clinical-ready asset, plus access to advanced AI-driven peptide drug discovery platform and innovative monthly dosing technology
AstraZeneca strengthens its weight management portfolio through a new strategic collaboration agreement with CSPC Pharmaceuticals to advance the development of multiple next-generation therapies for obesity and type 2 diabetes across eight programmes. Under this agreement, the...
|
|
|
|
|
|
|
|
|
|
|
29.01.26 - 23:54
|
XETR: CAPITAL ADJUSTMENT INFORMATION - 02.02.2026 - GB0009895292 (XETRA)
|
|
|
Das Instrument ZEG GB0009895292 ASTRAZENECA PLC DL-,25 EQUITY wird cum Kapitalmassnahme gehandelt am 30.01.2026 und ex Kapitalmassnahme am 02.02.2026
The instrument ZEG GB0009895292 ASTRAZENECA PLC DL-,25 EQUITY is traded cum capital adjustment on 30.01.2026 and ex capital adjustment on 02.02.2026...
|
|
|
29.01.26 - 23:51
|
XFRA: CAPITAL ADJUSTMENT INFORMATION - 02.02.2026 - GB0009895292 (XETRA)
|
|
|
Das Instrument ZEG GB0009895292 ASTRAZENECA PLC DL-,25 EQUITY wird cum Kapitalmassnahme gehandelt am 30.01.2026 und ex Kapitalmassnahme am 02.02.2026
The instrument ZEG GB0009895292 ASTRAZENECA PLC DL-,25 EQUITY is traded cum capital adjustment on 30.01.2026 and ex capital adjustment on 02.02.2026...
|
|
|
|
|
29.01.26 - 20:12
|
AstraZeneca to invest £11bn in China after rowing back on UK expansion (The Guardian)
|
|
|
Move comes after Britain's biggest drugmaker's dispute with government over drug pricingBritain's biggest drugmaker AstraZeneca is to invest $15bn (£11bn) in China, it announced during Keir Starmer's visit to the country, just months after cooling on plans for expansion in the UK.The Cambridge-based company said it would spend the money by 2030 to expand medicines manufacturing and research and development in China, where it already has a big presence. It includes the construction of a $2.5bn research hub in Beijing, which was announced last March. Continue reading......
|
|